Innoviva (INVA) Other Gross PP&E Adjustments (2010 - 2026)
Innoviva posted quarterly Other Gross PP&E Adjustments of -$30.7 million for Q1 2026, down 39.9% year-on-year from -$51.0 million in Q1 2025, and down 180.46% on a QoQ basis from -$10.9 million in Q4 2025.
Innoviva (INVA) has 12 years of Other Gross PP&E Adjustments data on file, last reported at -$30.7 million in Q1 2026.
- For the quarter ending Q1 2026, Other Gross PP&E Adjustments fell 39.9% year-over-year to -$30.7 million; the trailing twelve-month figure through Mar 2026 stood at -$30.7 million (down 39.9% YoY), and the FY2025 full-year result was -$10.9 million, down 345.54% from the prior year.
- Other Gross PP&E Adjustments for Q1 2026 stood at -$30.7 million, down from -$10.9 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$2.5 million in Q4 2024 and bottomed at -$30.7 million in Q1 2026.
- The 5-year median for Other Gross PP&E Adjustments is -$9.2 million (2024), against an average of -$11.1 million.
- The widest annual swing landed in 2022, when Other Gross PP&E Adjustments slumped 3265.98%; it then jumped 60.52% in 2023.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at -$3.3 million in 2022, then increased by 22.33% to -$2.5 million in 2023, then grew by 3.27% to -$2.5 million in 2024, then sank by 345.54% to -$10.9 million in 2025, then sank by 180.46% to -$30.7 million in 2026.
- The last three Other Gross PP&E Adjustments figures came in at -$30.7 million (Q1 2026), -$10.9 million (Q4 2025), and -$8.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | -30.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.65 Mn |
| Mar 31, 2026 | -30.65 Mn |
| Dec 31, 2025 | -10.93 Mn |
| Dec 31, 2025 | -10.93 Mn |
| Sep 30, 2025 | -8.00 Mn |
| Sep 30, 2025 | -8.00 Mn |
| Jun 30, 2025 | -14.96 Mn |
| Jun 30, 2025 | -14.96 Mn |
| Mar 31, 2025 | -21.91 Mn |
| Mar 31, 2025 | -21.91 Mn |
| Dec 31, 2024 | -2.45 Mn |
| Dec 31, 2024 | -2.45 Mn |
| Sep 30, 2024 | -9.19 Mn |
| Sep 30, 2024 | -9.19 Mn |
| Jun 30, 2024 | -16.02 Mn |
| Jun 30, 2024 | -16.02 Mn |
| Mar 31, 2024 | -21.67 Mn |
| Mar 31, 2024 | -21.67 Mn |
| Dec 31, 2023 | -2.54 Mn |
| Dec 31, 2023 | -2.54 Mn |
| Sep 30, 2023 | -2.83 Mn |
| Sep 30, 2023 | -2.83 Mn |
| Jun 30, 2023 | -15.72 Mn |
| Jun 30, 2023 | -15.72 Mn |
| Mar 31, 2023 | -14.57 Mn |
| Mar 31, 2023 | -14.57 Mn |
| Dec 31, 2022 | -3.27 Mn |
| Dec 31, 2022 | -3.27 Mn |
| Sep 30, 2022 | -7.18 Mn |
| Sep 30, 2022 | -7.18 Mn |
| Jun 30, 2022 | -3.55 Mn |
| Jun 30, 2022 | -3.55 Mn |
| Mar 31, 2022 | -3.79 Mn |
| Mar 31, 2022 | -3.79 Mn |
| Dec 31, 2021 | -97,000.00 |
| Dec 31, 2021 | -97,000.00 |
| Jun 30, 2019 | -1.35 Mn |
| Jun 30, 2019 | -1.35 Mn |
| Mar 31, 2019 | -1.42 Mn |
| Mar 31, 2019 | -1.42 Mn |
| Dec 31, 2014 | 324,000.00 |
| Dec 31, 2014 | 324,000.00 |
| Dec 31, 2013 | 62.04 Mn |
| Dec 31, 2013 | 62.04 Mn |
| Dec 31, 2012 | 58.57 Mn |
| Dec 31, 2012 | 58.57 Mn |
| Dec 31, 2011 | 57.56 Mn |
| Dec 31, 2011 | 57.56 Mn |
| Dec 31, 2010 | 53.86 Mn |
| Dec 31, 2010 | 53.86 Mn |